Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use

Helge H O Müller, Sebastian Moeller, Caroline Lücke, Alexandra P Lam, Niclas Braun, Alexandra Philipsen, Helge H O Müller, Sebastian Moeller, Caroline Lücke, Alexandra P Lam, Niclas Braun, Alexandra Philipsen

Abstract

In addition to electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS) is one of the approved neurostimulation tools for treatment of major depression. VNS is particularly used in therapy-resistant depression (TRD) and exhibits antidepressive and augmentative effects. In long-term treatment, up to two-thirds of patients respond. This mini-review provides a comprehensive overview of augmentation pharmacotherapy and neurostimulation-based treatment strategies, with a special focus on VNS in TRD, and provides practical clinical advice for how to select TRD patients for add-on neurostimulation treatment strategies.

Keywords: affective disorders; clinical practice; neurostimulation; therapy-resistant depression; vagus nerve stimulation.

Figures

Figure 1
Figure 1
Clinical pathways when choosing neurostimulation techniques.

References

    1. (2009). Yoga for anxiety and depression. Studies suggest that this practice modulates the stress response. Harv. Ment. Health Lett. 25, 4–5.
    1. (2010). Deep brain stimulation shows promise for Alzheimer's, depression treatment. Doctors also now have more options in how DBS is used to treat Parkinson's disease. Duke Med. Health News 16, 1–2.
    1. Aaronson S. T., Carpenter L. L., Conway C. R., Reimherr F. W., Lisanby S. H., Schwartz T. L., et al. . (2013). Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 6, 631–640. 10.1016/j.brs.2012.09.013
    1. Aaronson S. T., Sears P., Ruvuna F., Bunker M., Conway C. R., Dougherty D. D., et al. . (2017). A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am. J. Psychiatry 174, 640–648. 10.1176/appi.ajp.2017.16010034
    1. Allan C. L., Ebmeier K. P. (2011). The use of ECT and MST in treating depression. Int. Rev. Psychiatry 23, 400–412. 10.3109/09540261.2011.614223
    1. Andrade C. (2017). Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J. Clin. Psychiatry 78, e852–e857. 10.4088/JCP.17f11738
    1. Aronson R., Offman H. J., Joffe R. T., Naylor C. D. (1996). Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53, 842–848. 10.1001/archpsyc.1996.01830090090013
    1. Baeken C., De Raedt R., Van Hove C., Clerinx P., De Mey J., Bossuyt A. (2009). HF-rTMS treatment in medication-resistant melancholic depression: results from 18FDG-PET brain imaging. CNS Spectr. 14, 439–448. 10.1017/S1092852900020411
    1. Bakker N., Shahab S., Giacobbe P., Blumberger D. M., Daskalakis Z. J., Kennedy S. H., et al. (2015). rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz vs. intermittent theta-burst stimulation. Brain Stimul. 8, 208–215. 10.1016/j.brs.2014.11.002
    1. Bartoli F., Dell'Osso B., Crocamo C., Fiorillo A., Ketter T. A., Suppes T., et al. . (2017). Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: a meta-analysis. J. Psychiatr. Res. 88, 38–46. 10.1016/j.jpsychires.2016.12.021
    1. Beaucage C., Cardinal L., Kavanagh M., Aubé D. (2009). Major depression in primary care and clinical impacts of treatment strategies: a literature review. Sante. Ment. Que. 34, 77–100. 10.7202/029760ar
    1. Berlim M. T., McGirr A., Van den Eynde F., Fleck M. P., Giacobbe P. (2014). Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual cingulate cortex for treatment-resistant depression: a systematic review and exploratory meta-analysis. J. Affect. Disord. 159, 31–38. 10.1016/j.jad.2014.02.016
    1. Berlim M. T., Van den Eynde F., Daskalakis Z. J. (2013a). Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. J. Psychiatr. Res. 47, 1–7. 10.1016/j.jpsychires.2012.09.025
    1. Berlim M. T., Van den Eynde F., Daskalakis Z. J. (2013b). Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depress. Anxiety 30, 614–623. 10.1002/da.22060
    1. Berry S. M., Broglio K., Bunker M., Jayewardene A., Olin B., Rush A. J. (2013). A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med. Devices 6, 17–35. 10.2147/MDER.S41017
    1. Bschor T. (2010). Therapy-resistant depression. Expert Rev. Neurother. 10, 77–86. 10.1586/ern.09.137
    1. Buhmann C., Huckhagel T., Engel K., Gulberti A., Hidding U., Poetter-Nerger M., et al. . (2017). Adverse events in deep brain stimulation: a retrospective long-term analysis of neurological, psychiatric and other occurrences. PLoS ONE 12:e0178984. 10.1371/journal.pone.0178984
    1. Bulteau S., Sébille V., Fayet G., Thomas-Ollivier V., Deschamps T., Bonnin-Rivalland A., et al. . (2017). Efficacy of intermittent Theta Burst Stimulation (iTBS) and 10-Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant unipolar depression: study protocol for a randomised controlled trial. Trials 18:17. 10.1186/s13063-016-1764-8
    1. Cadieux R. J. (1998). Practical management of treatment-resistant depression. Am. Fam. Physician 58, 2059–2062.
    1. Calev A., Gaudino E. A., Squires N. K., Zervas I. M., Fink M. (1995). ECT and non-memory cognition: a review. Br. J. Clin. Psychol. 34 (Pt 4), 505–515. 10.1111/j.2044-8260.1995.tb01485.x
    1. Chae J. H., Nahas Z., Lomarev M., Denslow S., Lorberbaum J. P., Bohning D. E., et al. . (2003). A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J. Psychiatr. Res. 37, 443–455. 10.1016/S0022-3956(03)00074-8
    1. Charlson F., Siskind D., Doi S. A., McCallum E., Broome A., Lie D. C. (2012). ECT efficacy and treatment course: a systematic review and meta-analysis of twice vs. thrice weekly schedules. J. Affect. Disord. 138, 1–8. 10.1016/j.jad.2011.03.039
    1. Cusin C., Dougherty D. D. (2012). Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biol. Mood Anxiety Disord. 2:14. 10.1186/2045-5380-2-14
    1. De Fruyt J., Deschepper E., Audenaert K., Constant E., Floris M., Pitchot W., et al. . (2012). Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J. Psychopharmacol. 26, 603–617. 10.1177/0269881111408461
    1. DeGiorgio C. M., Schachter S. C., Handforth A., Salinsky M., Thompson J., Uthman B., et al. . (2000). Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 41, 1195–1200. 10.1111/j.1528-1157.2000.tb00325.x
    1. Dell'Osso B., Altamura A. C. (2014). Transcranial brain stimulation techniques for major depression: should we extend TMS lessons to tDCS? Clin. Pract. Epidemiol. Ment. Health 10, 92–93. 10.2174/1745017901410010092
    1. Dell'osso B., Camuri G., Castellano F., Vecchi V., Benedetti M., Bortolussi S., et al. . (2011). Meta-review of metanalytic studies with repetitive transcranial magnetic stimulation (rTMS) for the treatment of major depression. Clin. Pract. Epidemiol. Ment. Health 7, 167–177. 10.2174/1745017901107010167
    1. Demirtas-Tatlidede A., Vahabzadeh-Hagh A. M., Pascual-Leone A. (2013). Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology 64, 566–578. 10.1016/j.neuropharm.2012.06.020
    1. Dording C. M. (2000). Antidepressant augmentation and combinations. Psychiatr. Clin. North Am. 23, 743–755. 10.1016/S0193-953X(05)70195-7
    1. Edwards S. J., Hamilton V., Nherera L., Trevor N. (2013). Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol. Assess. 17, 1–190. 10.3310/hta17540
    1. Edwards S. J., Wakefield V., Nherera L., Trevor N. (2014). Systematic review and mixed treatment comparison of lithium or an atypical anti-psychotic (AAP) used to augment a selective serotonin reuptake inhibitor (SSRI) in treatment resistant depression (TRD). Value Health 17:A455. 10.1016/j.jval.2014.08.1242
    1. Effinger J. M., Stewart D. G. (2012). Classification of co-occurring depression and substance abuse symptoms predicts suicide attempts in adolescents. Suicide Life Threat. Behav. 42, 353–358. 10.1111/j.1943-278X.2012.00092.x
    1. Elliott R. E., Morsi A., Tanweer O., Grobelny B., Geller E., Carlson C., et al. . (2011). Efficacy of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS > 10 years. Epilepsy Behav. 20, 478–483.
    1. Eschweiler G. W., Vonthein R., Bode R., Huell M., Conca A., Peters O., et al. . (2007). Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression. J. Affect. Disord. 101, 149–157. 10.1016/j.jad.2006.11.012
    1. Fava M., Davidson K. G. (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19, 179–200. 10.1016/S0193-953X(05)70283-5
    1. Feldman R. L., Dunner D. L., Muller J. S., Stone D. A. (2013). Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J. Med. Econ. 16, 62–74. 10.3111/13696998.2012.724745
    1. Feusner J. D., Madsen S., Moody T. D., Bohon C., Hembacher E., Bookheimer S. Y., et al. . (2012). Effects of cranial electrotherapy stimulation on resting state brain activity. Brain Behav. 2, 211–220. 10.1002/brb3.45
    1. Fornaro M., Stubbs B., De Berardis D., Perna G., Valchera A., Veronese N., et al. . (2016). Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int. J. Mol. Sci. 17:241. 10.3390/ijms17020241
    1. Fraguas D., Merchan-Náranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., et al. . (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J. Clin. Psychiatry 69, 1166–1175. 10.4088/JCP.v69n0717
    1. Gabriel A. (2013). Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study. Neuropsychiatr. Dis. Treat. 9, 485–492. 10.2147/NDT.S42745
    1. Gilula M. F., Barach P. R. (2004). Cranial electrotherapy stimulation: a safe neuromedical treatment for anxiety, depression, or insomnia. South Med. J. 97, 1269–1270. 10.1097/01.SMJ.0000136304.33212.06
    1. Gunther M., Phillips K. D. (2010). Cranial electrotherapy stimulation for the treatment of depression. J. Psychosoc. Nurs. Ment. Health Serv. 48, 37–42. 10.3928/02793695-20100701-01
    1. Hayes S. C., Hofmann S. G. (2017). The third wave of cognitive behavioral therapy and the rise of process-based care. World Psychiatry 16, 245–246. 10.1002/wps.20442
    1. Henry T. R. (2002). Therapeutic mechanisms of vagus nerve stimulation. Neurology 59, S3–S14. 10.1212/WNL.59.6_suppl_4.S3
    1. Hincapie-Castillo J. M., Daniels P. F. (2017). Use of lithium in patients with unipolar depression. Lancet Psychiatry 4, 662–663. 10.1016/S2215-0366(17)30317-6
    1. Holtzmann J., Richieri R., Saba G., Allaïli N., Bation R., Moliere F., et al. . (2016). [How to define treatment-resistant depression?]. Presse Med. 45, 323–328. 10.1016/j.lpm.2016.02.002
    1. Hunot V., Moore T. H., Caldwell D. M., Furukawa T. A., Davies P., Jones H., et al. (2013). ‘Third wave’ cognitive and behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst. Rev. CD008704 10.1002/14651858.CD008704.pub2
    1. Jiménez F., Nicolini H., Lozano A. M., Piedimonte F., Salín R., Velasco F. (2013). Electrical stimulation of the inferior thalamic peduncle in the treatment of major depression and obsessive compulsive disorders. World Neurosurg. 80, S30.e17– S30.e25. 10.1016/j.wneu.2012.07.010
    1. Kato M., Chang C. M. (2013). Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs 27(Suppl. 1), S11–S19. 10.1007/s40263-012-0029-7
    1. Kavirajan H. C., Lueck K., Chuang K. (2014). Alternating current cranial electrotherapy stimulation (CES) for depression. Cochrane Database Syst. Rev. CD010521. 10.1002/14651858.CD010521.pub2
    1. Kedzior K. K., Reitz S. K., Azorina V., Loo C. (2015). Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. Depress. Anxiety 32, 193–203. 10.1002/da.22339
    1. Kedzior K. K., Schuchinsky M., Gerkensmeier I., Loo C. (2017). Challenges in comparing the acute cognitive outcomes of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) vs. electroconvulsive therapy (ECT) in major depression: a systematic review. J. Psychiatr. Res. 91, 14–17. 10.1016/j.jpsychires.2017.03.002
    1. Kellner C. (2014). Review: maintenance antidepressants reduce risk of relapse in the 6 months following ECT in people with major depression. Evid. Based Ment. Health 17:8. 10.1136/eb-2013-101663
    1. Kellner C. H., Greenberg R. M., Murrough J. W., Bryson E. O., Briggs M. C., Pasculli R. M. (2012). ECT in treatment-resistant depression. Am. J. Psychiatry 169, 1238–1244. 10.1176/appi.ajp.2012.12050648
    1. Kellner C. H., Knapp R. G., Petrides G., Rummans T. A., Husain M. M., Rasmussen K., et al. . (2006). Continuation electroconvulsive therapy vs. pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch. Gen. Psychiatry 63, 1337–1344. 10.1001/archpsyc.63.12.1337
    1. Kennedy S. H., Giacobbe P., Rizvi S. J., Placenza F. M., Nishikawa Y., Mayberg H. S., et al. . (2011). Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am. J. Psychiatry 168, 502–510. 10.1176/appi.ajp.2010.10081187
    1. Kho K. H., van Vreeswijk M. F., Simpson S., Zwinderman A. H. (2003). A meta-analysis of electroconvulsive therapy efficacy in depression. J. ECT 19, 139–147. 10.1097/00124509-200309000-00005
    1. Kirsch D. L., Nichols F. (2013). Cranial electrotherapy stimulation for treatment of anxiety, depression, and insomnia. Psychiatr. Clin. North Am. 36, 169–176. 10.1016/j.psc.2013.01.006
    1. Kirsch D. L., Price L. R., Nichols F., Marksberry J. A., Platoni K. T. (2014). Military service member and veteran self reports of efficacy of cranial electrotherapy stimulation for anxiety, posttraumatic stress disorder, insomnia, and depression. US Army Med. Dep. J. 46–54.
    1. Kito S. (2017). [Magnetic stimulation therapy for mood disorder]. Brain Nerve 69, 239–246. 10.11477/mf.1416200733
    1. Kosel M., Schlaepfer T. E. (2003). Beyond the treatment of epilepsy: new applications of vagus nerve stimulation in psychiatry. CNS Spectr. 8, 515–521. 10.1017/S1092852900018988
    1. Lasserre A. M., Strippoli M. F., Glaus J., Gholam-Rezaee M., Vandeleur C. L., Castelao E., et al. . (2017). Prospective associations of depression subtypes with cardio-metabolic risk factors in the general population. Mol. Psychiatry 22, 1026–1034. 10.1038/mp.2016.178
    1. Liebetanz D., Fregni F., Monte-Silva K. K., Oliveira M. B., Amâncio-dos-Santos A., Nitsche M. A., et al. . (2006). After-effects of transcranial direct current stimulation (tDCS) on cortical spreading depression. Neurosci. Lett. 398, 85–90. 10.1016/j.neulet.2005.12.058
    1. Lisanby S. H., Luber B., Schlaepfer T. E., Sackeim H. A. (2003). Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 28, 1852–1865. 10.1038/sj.npp.1300229
    1. Lozano A. M., Lipsman N. (2013). Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 77, 406–424. 10.1016/j.neuron.2013.01.020
    1. Lucas N., Hubain P., Loas G., Jurysta F. (2017). Treatment resistant depression: actuality and perspectives in 2017. Rev. Med. Brux. 38, 16–25.
    1. Manetti A., Hoertel N., Le Strat Y., Schuster J. P., Lemogne C., Limosin F. (2014). Comorbidity of late-life depression in the United States: a population-based study. Am. J. Geriatr. Psychiatry 22, 1292–1306. 10.1016/j.jagp.2013.05.001
    1. Marangell L. B., Rush A. J., George M. S., Sackeim H. A., Johnson C. R., Husain M. M., et al. . (2002). Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol. Psychiatry 51, 280–287. 10.1016/S0006-3223(01)01343-9
    1. Maske U. E., Busch M. A., Jacobi F., Beesdo-Baum K., Seiffert I., Wittchen H. U., et al. . (2015). Current major depressive syndrome measured with the Patient Health Questionnaire-9 (PHQ-9) and the Composite International Diagnostic Interview (CIDI): results from a cross-sectional population-based study of adults in Germany. BMC Psychiatry 15:77. 10.1186/s12888-015-0463-4
    1. McClintock S. M., Reti I. M., Carpenter L. L., McDonald W. M., Dubin M., Taylor S. F., et al. . (2018). Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J. Clin. Psychiatry 79:16cs10905. 10.4088/JCP.16cs10905
    1. McCullough J. P., Jr. (2003). Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP). J. Clin. Psychol. 59, 833–846. 10.1002/jclp.10176
    1. McLachlan R. S. (1997). Vagus nerve stimulation for intractable epilepsy: a review. J. Clin. Neurophysiol. 14, 358–368. 10.1097/00004691-199709000-00002
    1. Meron D., Hedger N., Garner M., Baldwin D. S. (2015). Transcranial direct current stimulation (tDCS) in the treatment of depression: systematic review and meta-analysis of efficacy and tolerability. Neurosci. Biobehav. Rev. 57, 46–62. 10.1016/j.neubiorev.2015.07.012
    1. Michaud C. M., Murray C. J., Bloom B. R. (2001). Burden of disease–implications for future research. JAMA 285, 535–539. 10.1001/jama.285.5.535
    1. Minichino A., Bersani F. S., Capra E., Pannese R., Bonanno C., Salviati M., et al. . (2012). ECT, rTMS, and deepTMS in pharmacoresistant drug-free patients with unipolar depression: a comparative review. Neuropsychiatr. Dis. Treat. 8, 55–64. 10.2147/NDT.S27025
    1. Mojtabai R. (2017). Nonremission and time to remission among remitters in major depressive disorder: revisiting STAR*D. Depress. Anxiety 34, 1123–1133. 10.1002/da.22677
    1. Müller H. H., Kornhuber J., Maler J. M., Sperling W. (2013a). The effects of stimulation parameters on clinical outcomes in patients with vagus nerve stimulation implants with major depression. J. ECT 29, e40–e42. 10.1097/YCT.0b013e318290f7ed
    1. Müller H. H. O., Lücke C., Moeller S., Philipsen A., Sperling W. (2017a). Efficacy and long-term tuning parameters of vagus nerve stimulation in long-term treated depressive patients. J. Clin. Neurosci. 44, 340–341. 10.1016/j.jocn.2017.06.020
    1. Müller H. H. O., Reike M., Grosse-Holz S., Röther M., Lücke C., Philipsen A., et al. . (2017b). Electroconvulsive therapy hasn't negative effects on short-term memory function, as assessed using a bedside hand-held device. Ment. Illn. 9:7093. 10.4081/mi.2017.7093
    1. Müller H. H., Reulbach U., Maler J. M., Kornhuber J., Sperling W. (2013b). Facilitative effects of VNS on the motor threshold: implications for its antidepressive mode of action? J. Neural. Transm. 120, 1507–1510. 10.1007/s00702-013-1043-8
    1. Murphy J. A., Sarris J., Byrne G. J. (2017). A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depress. Res. Treat. 2017:4176825. 10.1155/2017/4176825
    1. Nahas Z., Burns C., Foust M. J., Short B., Herbsman T., George M. S. (2006). Vagus nerve stimulation (VNS) for depression: what do we know now and what should be done next? Curr. Psychiatry Rep. 8, 445–451. 10.1007/s11920-006-0049-4
    1. Nelson J. C. (2015). Adjunctive ziprasidone in major depression and the current status of adjunctive atypical antipsychotics. Am. J. Psychiatry 172, 1176–1178. 10.1176/appi.ajp.2015.15091220
    1. Nelson J. C., Baumann P., Delucchi K., Joffe R., Katona C. (2014). A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J. Affect. Disord. 168, 269–275. 10.1016/j.jad.2014.05.053
    1. Ng W. H., Donner E., Go C., Abou-Hamden A., Rutka J. T. (2010). Revision of vagal nerve stimulation (VNS) electrodes: review and report on use of ultra-sharp monopolar tip. Childs Nerv. Syst. 26, 1081–1084. 10.1007/s00381-010-1121-2
    1. Nierenberg A. A., Alpert J. E., Gaynes B. N., Warden D., Wisniewski S. R., Biggs M. M., et al. . (2008). Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J. Affect. Disord. 108, 129–134. 10.1016/j.jad.2007.10.011
    1. Oldham M. A., Ciraulo D. A. (2014). Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system. Chronobiol. Int. 31, 305–319. 10.3109/07420528.2013.833935
    1. Pagnin D., de Queiroz V., Pini S., Cassano G. B. (2004). Efficacy of ECT in depression: a meta-analytic review. J. ECT 20, 13–20. 10.1097/00124509-200403000-00004
    1. Palm U., Ayache S. S., Padberg F., Lefaucheur J. P. (2016a). [Transcranial direct current stimulation (tDCS) for depression: results of nearly a decade of clinical research]. Encephale 42, 39–47. 10.1016/j.encep.2015.06.003
    1. Palm U., Hasan A., Strube W., Padberg F. (2016b). tDCS for the treatment of depression: a comprehensive review. Eur. Arch. Psychiatry Clin. Neurosci. 266, 681–694. 10.1007/s00406-016-0674-9
    1. Perera T., George M. S., Grammer G., Janicak P. G., Pascual-Leone A., Wirecki T. S. (2016). The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 9, 336–346. 10.1016/j.brs.2016.03.010
    1. Pinna M., Manchia M., Oppo R., Scano F., Pillai G., Loche A. P., et al. . (2016). Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neurosci. Lett. 669, 32–42. 10.1016/j.neulet.2016.10.047
    1. Post T., Kemmler G., Krassnig T., Brugger A., Hausmann A. (2015). [Efficacy of continuation and maintenance electroconvulsive therapy (c/m ECT) in the treatment of patients with therapy-resistant affective disorders: a retrospective analysis]. Neuropsychiatrie 29, 133–138. 10.1007/s40211-015-0150-1
    1. Prudic J. (2008). Strategies to minimize cognitive side effects with ECT: aspects of ECT technique. J. ECT 24, 46–51. 10.1097/YCT.0b013e31815ef238
    1. Rachid F. (2018). Maintenance repetitive transcranial magnetic stimulation (rTMS) for relapse prevention in with depression: a review. Psychiatry Res. 262, 363–372. 10.1016/j.psychres.2017.09.009
    1. Rifkin A. (1988). ECT versus tricyclic antidepressants in depression: a review of the evidence. J. Clin. Psychiatry 49, 3–7.
    1. Rizzo M., Creed F., Goldberg D., Meader N., Pilling S. (2011). A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. J. Psychosom. Res. 71, 18–27. 10.1016/j.jpsychores.2011.02.011
    1. Rush A. J., Kraemer H. C., Sackeim H. A., Fava M., Trivedi M. H., Frank E., et al. . (2006a). Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31, 1841–1853. 10.1038/sj.npp.1301131
    1. Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., et al. . (2006b). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917. 10.1176/ajp.2006.163.11.1905
    1. Rutecki P. (1990). Anatomical, physiological, and theoretical basis for the antiepileptic effect of vagus nerve stimulation. Epilepsia 31(Suppl. 2), S1–S6. 10.1111/j.1528-1157.1990.tb05843.x
    1. Sackeim H. A., Rush A. J., George M. S., Marangell L. B., Husain M. M., Nahas Z., et al. . (2001). Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 25, 713–728. 10.1016/S0893-133X(01)00271-8
    1. Sakurai H., Suzuki T., Yoshimura K., Mimura M., Uchida H. (2017). Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology 234, 2453–2461. 10.1007/s00213-017-4634-5
    1. Schlaepfer T. E., Lieb K. (2005). Deep brain stimulation for treatment of refractory depression. Lancet 366, 1420–1422. 10.1016/S0140-6736(05)67582-4
    1. Schneider U. C., Bohlmann K., Vajkoczy P., Straub H. B. (2015). Implantation of a new Vagus Nerve Stimulation (VNS) Therapy(R) generator, AspireSR(R): considerations and recommendations during implantation and replacement surgery–comparison to a traditional system. Acta Neurochir. 157, 721–728. 10.1007/s00701-015-2362-3
    1. Serafini G., Gonda X., Rihmer Z., Pompili M., Girardi P., Nasrallah H. A., et al. . (2015). NMDA receptor antagonists for depression: critical considerations. Ann. Clin. Psychiatry 27, 213–220.
    1. Serafini G., Howland R. H., Rovedi F., Girardi P., Amore M. (2014). The role of ketamine in treatment-resistant depression: a systematic review. Curr. Neuropharmacol. 12, 444–461. 10.2174/1570159X12666140619204251
    1. Shirzadi A. A., Ghaemi S. N. (2006). Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry 14, 152–164. 10.1080/10673220600748486
    1. Sidhom E., Youssef N. A. (2014). Ultra-brief pulse unilateral ECT is associated with less cognitive side effects. Brain Stimul. 7, 768–769. 10.1016/j.brs.2014.06.013
    1. Slepecky M., Kotianova A., Prasko J., Majercak I., Gyorgyova E., Kotian M., et al. . (2017). Which psychological, psychophysiological, and anthropometric factors are connected with life events, depression, and quality of life in patients with cardiovascular disease. Neuropsychiatr. Dis. Treat. 13, 2093–2104. 10.2147/NDT.S141811
    1. Spielmans G. I., Berman M. I., Linardatos E., Rosenlicht N. Z., Perry A., Tsai A. C. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 10:e1001403. 10.1371/journal.pmed.1001403
    1. Stage K. B., Kristoffersen J., Sørensen C. H. (2007). Lithium versus antidepressants in prevention of unipolar depression. A survey of a Cochrane review. Ugeskr Laeger 169, 3953–3955.
    1. Sykes D. A., Moore H., Stott L., Holliday N., Javitch J. A., Lane J. R., et al. . (2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat. Commun. 8:763. 10.1038/s41467-017-00716-z
    1. Temmingh H. S. (2012). Extrapyramidal side-effects and antipsychotics: are second-generation agents still indicated? Br. J. Psychiatry 201:247. 10.1192/bjp.201.3.247
    1. Tesio V., Marra S., Molinaro S., Torta R., Gaita F., Castelli L. (2017). Screening of depression in cardiology: a study on 617 cardiovascular patients. Int. J. Cardiol. 245, 49–51. 10.1016/j.ijcard.2017.07.065
    1. The UK ECT Review Group (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799–808. 10.1016/S0140-6736(03)12705-5
    1. Topfer L. A., Hailey D. (2001). Vagus nerve stimulation (VNS) for treatment-resistant depression. Issues Emerg. Health Technol. 25, 713–728.
    1. Tschirdewahn J., Vignaud P., Pfeiffer A., Nolden J., Padberg F., Palm U. (2015). Transcranial direct current stimulation (tDCS) for the treatment of depression. MMW Fortschr. Med. 157, 46–48. 10.1007/s15006-015-7540-y
    1. Uthman B. M., Wilder B. J., Hammond E. J., Reid S. A. (1990). Efficacy and safety of vagus nerve stimulation in patients with complex partial seizures. Epilepsia 31(Suppl. 2), S44–S50. 10.1111/j.1528-1157.1990.tb05849.x
    1. Vandeleur C. L., Fassassi S., Castelao E., Glaus J., Strippoli M. F., Lasserre A. M., et al. . (2017). Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 250, 50–58. 10.1016/j.psychres.2017.01.060
    1. Warden D., Rush A. J., Wisniewski S. R., Lesser I. M., Kornstein S. G., Balasubramani G. K., et al. . (2009). What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int. J. Neuropsychopharmacol. 12, 459–473. 10.1017/S1461145708009073
    1. Wiles N., Thomas L., Abel A., Barnes M., Carroll F., Ridgway N., et al. . (2014). Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. Health Technol. Assess. 18, 1–167, vii–viii. 10.3310/hta18310
    1. Wright B. M., Eiland E. H., III., Lorenz R. (2013). Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 33, 344–359. 10.1002/phar.1204
    1. Young A. H. (2013). Review: lithium reduces the risk of suicide compared with placebo in people with depression and bipolar disorder. Evid. Based Ment. Health 16, 112. 10.1136/eb-2013-101493
    1. Zhou X., Ravindran A. V., Qin B., Del Giovane C., Li Q., Bauer M., et al. . (2015). Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J. Clin. Psychiatry 76, e487–e498. 10.4088/JCP.14r09204

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit